Literature DB >> 9571950

Relationship of 31P MR spectroscopy to the histopathological grading of chronic hepatitis and response to therapy.

K Kiyono1, A Shibata, S Sone, T Watanabe, M Oguchi, N Shikama, T Ichijo, K Kiyosawa, T Sodeyama.   

Abstract

PURPOSE: In vivo phosphorus-31 MR spectroscopy (31P MRS) was performed in the human liver in order to investigate the relation between: the ratios of phosphorus metabolites in the liver; the histopathological grading of chronic hepatitis; and the response to therapy.
MATERIAL AND METHODS: Hepatic 31P MRS using the DRESS method (depth-resolved surface-coil spectroscopy) was carried out in 45 patients with chronic viral hepatitis or autoimmune hepatitis, and in 16 control subjects. We measured the ratios of the peak areas of phosphomonoesters (PME), inorganic phosphate (Pi), or phosphodiesters (PDE) to the peak area of beta-adenosine triphosphate (ATP).
RESULTS: The PDE/ATP ratio of patients with chronic hepatitis or liver cirrhosis was lower than that of control subjects (liver cirrhosis = 0.74; chronic active hepatitis = 1.13-1.21; normal = 1.43); only a small difference was found in the PME/ATP and Pi/ATP ratios. There was no correlation between the spectra and histopathological grading or response to therapy, but the response to therapy was poor when a reduced PDE/ATP ratio was present.
CONCLUSION: The PDE/ATP ratio measured by 31P MRS makes it possible to identify the transition of chronic active hepatitis into liver cirrhosis with a poor response to therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9571950     DOI: 10.1080/02841859809172201

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  8 in total

1.  Etiology and functional status of liver cirrhosis by 31P MR spectroscopy.

Authors:  Monika Dezortova; Pavel Taimr; Antonin Skoch; Julius Spicak; Milan Hajek
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

2.  A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis.

Authors:  Edmund M Godfrey; Andrew J Patterson; Andrew N Priest; Susan E Davies; Ilse Joubert; Anant S Krishnan; Nyree Griffin; Ashley S Shaw; Graeme J Alexander; Michael E Allison; William J H Griffiths; Alexander E S Gimson; David J Lomas
Journal:  Eur Radiol       Date:  2012-07-01       Impact factor: 5.315

3.  3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.

Authors:  Chun-Yu Zhang; Qian Zhang; Hui-Mao Zhang; Hai-Shan Yang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

4.  In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease.

Authors:  A Orlacchio; F Bolacchi; M Angelico; A Mancini; V Cozzolino; M Cadioli; G Simonetti
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

Review 5.  Noninvasive diagnosis of cirrhosis: a review of different imaging modalities.

Authors:  Riccardo De Robertis; Mirko D'Onofrio; Emanuele Demozzi; Stefano Crosara; Stefano Canestrini; Roberto Pozzi Mucelli
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Absolute quantification of human liver metabolite concentrations by localized in vivo 31P NMR spectroscopy in diffuse liver disease.

Authors:  Bengt Norén; Peter Lundberg; Marcus Ressner; Staffan Wirell; Sven Almer; Orjan Smedby
Journal:  Eur Radiol       Date:  2004-09-03       Impact factor: 5.315

7.  Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using 1H and 31P magnetic resonance spectroscopy.

Authors:  Steven F Solga; Alena Horska; Susanne Hemker; Stephen Crawford; Charalett Diggs; Anna Mae Diehl; Frederick L Brancati; Jeanne M Clark
Journal:  Liver Int       Date:  2008-03-04       Impact factor: 5.828

8.  Measuring short-term liver metabolism non-invasively: postprandial and post-exercise ¹H and ³¹P MR spectroscopy.

Authors:  Antti Hakkarainen; Jesper Lundbom; Esa K Tuominen; Marja-Riitta Taskinen; Kirsi H Pietiläinen; Nina Lundbom
Journal:  MAGMA       Date:  2014-06-04       Impact factor: 2.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.